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Abstract
Transmissible spongiform encephalopathies (TSE) or prion diseases are neurodegenerative disorders associated with
conversion of normal host prion protein (PrP) to a misfolded, protease-resistant form (PrPres). Genetic variations of prion
protein in humans and animals can alter susceptibility to both familial and infectious prion diseases. The N171S PrP
polymorphism is found mainly in humans of African descent, but its low incidence has precluded study of its possible
influence on prion disease. Similar to previous experiments of others, for laboratory studies we created a transgenic model
expressing the mouse PrP homolog, PrP-170S, of human PrP-171S. Since PrP polymorphisms can vary in their effects on
different TSE diseases, we tested these mice with four different strains of mouse-adapted scrapie. Whereas 22L and ME7
scrapie strains induced typical clinical disease, neuropathology and accumulation of PrPres in all transgenic mice at 99-128
average days post-inoculation, strains RML and 79A produced clinical disease and PrPres formation in only a small subset of
mice at very late times. When mice expressing both PrP-170S and PrP-170N were inoculated with RML scrapie, dominant-
negative inhibition of disease did not occur, possibly because interaction of strain RML with PrP-170S was minimal.
Surprisingly, in vitro PrP conversion using protein misfolding cyclic amplification (PMCA), did not reproduce the in vivo
findings, suggesting that the resistance noted in live mice might be due to factors or conditions not present in vitro. These
findings suggest that in vivo conversion of PrP-170S by RML and 79A scrapie strains was slow and inefficient. PrP-170S mice
may be an example of the conformational selection model where the structure of some prion strains does not favor
interactions with PrP molecules expressing certain polymorphisms.
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Introduction
TSE or prion diseases are transmissible neurodegenerative
diseases occurring in a variety of mammalian species including
domestic and wild animals as well as humans [1]. Examples
include scrapie in sheep, chronic wasting disease (CWD) in cervids
and bovine spongiform encephalopathy (BSE) in cattle. Human
diseases include sporadic and variant Creutzfeldt-Jakob disease
(sCJD and vCJD) and familial diseases such as Gerstmann–
Stra ¨ussler–Scheinker syndrome (GSS), Fatal Familial Insomnia
(FFI) and familial CJD. A hallmark of prion diseases is the
conversion of the normal protease-sensitive host prion protein
(PrPsen) into a misfolded partially protease-resistant form (PrPres)
which may be in part responsible for the generation of the disease
[2]. PrP expression is required for prion disease, and PrP knockout
mice are resistant to both infection and disease [3].
PrPgenepolymorphismsoccurnaturallyinmanyspecies.Inboth
sheep and in mice such polymorphisms have been found to
influence susceptibility to scrapie infection and disease. For
example, sheep expressing Alanine, Arginine, Arginine at positions
136, 154 and 171 (A136R154R171) respectively, are highly resistant to
most strains of sheep scrapie [4,5,6]. However, recent observations
indicate that sheep with the A136R154R171 genotype can be
susceptible to atypical scrapie (Nor98) suggesting that resistance
might be strain specific [7,8]. Similarly in inbred mice there are two
known PrP alleles (Prnp
a and Prnp
b) which are characterized by
amino acid differences at PrP residues 108 and 189 [9,10,11]. Mice
with Prnp
a have short incubation times with one set of scrapie
strains and prolonged incubation times with another set, while mice
with Prnp
b show an opposite pattern of incubation times with these
same scrapie strains [12,13]. Thus there is a different strain-specific
pattern of susceptibility associated with each of these Prnp
genotypes.
In humans, the methionine vs. valine polymorphism at PrP
residue 129 appears to influence the clinical phenotype of familial
prion disease associated with the D178N PrP mutation [14,15], as
well as susceptibility to sCJD, vCJD and kuru [16,17,18,19,20]. In
addition, the human polymorphism E219K may be associated
with resistance to sCJD [21], but does not appear to correlate with
resistance to vCJD in humans or mouse models [22,23]. The
human PrP polymorphism, G127V, was recently shown to be
associated with resistance to kuru [24]. Other naturally occurring
human polymorphisms, such as G142S and N171S, have not been
tested for prion disease susceptibility [25].
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Jamaicans and Sardinians [26]. The rarity of this polymorphism
and the fact that it is present mainly in geographical regions with
limited CJD surveillance make it difficult to detect possible
associations with prion disease. Therefore, in order to initiate
laboratory studies of the possible effects of this polymorphism on
TSE diseases and possibly also other CNS disorders, we generated
transgenic mice expressing mouse PrP-170S, the mouse homolog
of human PrP-171S (Table 1).
This approach of using transgenic mice expressing mouse or
hamster PrP with human PrP mutations and/or polymorphic
residues at homologous sites has been taken in numerous previous
studies of prion diseases. These include important studies of
models of Gerstmann-Stra ¨ussler-Scheinker syndrome (GSS)
[27,28,29,30,31,32], FFI [33] and familial CJD [34,35], as well
as a non-infectious neurodegenerative disease associated with
expression of prion protein with a nine octapeptide insertion [36].
In addition, transgenic mice expressing mouse PrP with cervid PrP
residues associated with a ‘‘rigid loop’’ in PrP have also revealed
interesting in vivo pathogenic effects [37,38].
Because PrP variations in animals and humans can have
different effects on different TSE strains, we tested our mice with
four different scrapie strains which have been maintained in
continuous mouse passage for many years. In these studies PrP-
170S expressing mice were highly susceptible to scrapie strains
22L and ME7, but were markedly resistant to scrapie strains RML
and 79A. In contrast, control mice were susceptible to all four
strains. This in vivo strain-specific influence on scrapie suscepti-
bility was not reproduced in cell-free in vitro PrP conversion
studies, suggesting that in vivo conditions not replicated in our in
vitro system were required. PrP-170S transgenic mice appear to be
an interesting new model to study the interactions between TSE
agent strains and PrP.
Materials and Methods
Ethics statement
All mice were housed at the Rocky Mountain Laboratories
(RML) in an AAALAC-accredited facility and experimentation
followed NIH RML Animal Care and Use Committee approved
protocols (NIH/RML Protocol #2007-31). This study was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health.
Generation of transgenic mice
To study the effect of the human N171S PrP polymorphism (Ref
SNP#rs16990018) we constructed transgenic mice expressing
serine instead of asparagine at mouse PrP residue 170 (homologous
to human PrP residue 171) (Table 1). The mutation was made at
residue 170 in mouse PrP using a cDNA clone of mouse PrP, p1-5
(E48-16) [39] using oligonucleotides 2077U (59- CCA GTG GAT
CAG TAC AGC AGC CAG AAC AAC TTC GTG C -39)a n d
2078L (59- GCA CGA AGT TGT TCT GGC TGC TGT ACT
GAT CCA CTG G -39) with a site directed mutagenesis kit
(Stratagene/Agilent, Santa Clara, CA). The plasmid with the
mutation was recloned, and the mutation was confirmed by
sequencing. A DNA fragment from PshAI to SfoI with PrP
sequences containing the mutation was excised, purified and
religated into a subclone, p44-3 (E58-6) [39,40], derived from the
pHGPrPhalf-genomic clone [41] by digestingwithAgeI and SfoI to
remove a portion of the PrP ORF and replacing this segment with
an oligonucleotide polylinker containing these and other sites.
Upstream sequences previously excised between two BamHI sites to
remove an unwanted SfoI site were replaced by digestion with
adjacent sites NotI and BspEI and the original 6.2kb fragment from
PHGPrP was reinserted. The resulting plasmid, p188-6, was
digested with NotI and SbfI to separate mouse sequences from
bacterialplasmidsequences,andthefragmentcontainingthemouse
sequences was used to inoculate C57BL/6 mouse eggs to generate
transgenic mice expressing PrP-170S [39]. Of the five transgenic
founding lines produced, three lines (Tg330, Tg340 and Tg290)
were selected for experimentation. These transgenic lines were
hemizygous for the transgene and homozygous for Prnp, the gene
encoding normal mouse PrP (MoPrP). The Prnp gene encoding
PrP-170N in C57BL/6 mice was removed by serial backcrossing to
C57BL/10Sn mice with a knocked-out Prnp gene (B10 PrP-/-)
derived from the original Edinburgh Prnp knockout mouse as
previously described [39,42]. Transgenic lines were maintained as
transgene heterozygotes by crossing to C57BL/10 PrP-/- mice and
selection of transgene positive mice by PCR analysis of tail DNA.
Table 1. Comparison of PrP residues in humans, mice and
transgenic mice generated in the present study.
Human
residue 165 166 167 168 169 170 171 172 173 174 175
Mouse residue 164 165 166 167 168 169 170 171 172 173 174
Human P M D E Y S N/S
a QNNF
Mouse P V D Q Y S N QNNF
Transgenic
mice
b
PVDQYSS QNNF
a- Naturally occurring polymorphism at human PrP residue 171 (see [26] for
review).
b- In the present study mouse residue 170 was mutated to generate 3 lines of
transgenic mice (Tg330,Tg340, and Tg290). Human PrP residue 171 is
homologous to mouse PrP residue 170.
doi:10.1371/journal.ppat.1002275.t001
Author Summary
Transmissible spongiform encephalopathies (TSE) or prion
diseases are infectious fatal neurological diseases that
affect many mammals, including humans. In these diseases
a misfolded form of host prion protein (PrP) leads to brain
degeneration and death. The genetic code of PrP in
individual animals or humans has minor variations, which
in some cases are associated with altered susceptibility to
disease. In humans a variation at residue 171 (N171S) has
been found in people mainly of African descent. However,
due to the low incidence of the variation and difficult
accessibility of these individuals, studies of prion diseases
in these populations have not been carried out. Therefore,
to create a laboratory animal model to study the effect of
this variation on prion diseases, we generated transgenic
mice expressing the mouse version of the human PrP
variation at residue 171. We then studied the susceptibility
of these mice to 4 strains of mouse-adapted scrapie. In our
experiments these transgenic mice were uniquely resistant
to two scrapie strains, but showed high sensitivity to two
others. This resistance appeared to be related to a slow or
inefficient generation of the aggregated disease-associat-
ed form of PrP in these mice, and was not duplicated using
in vitro assays. In summary, transgenic mice expressing this
variant PrP provide an interesting model to study
differences among prion strains and their interactions
with PrP in vivo.
Strain-Specific Scrapie Resistance
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previously described [39]. Briefly, detection of the modified knock-
out version of Prnp and the neo cassette in the PrP-/- mice was
accomplished using primers RK1 and Mut217 as previously
described [43]. These primers yielded a C57BL/10 MoPrP
product of approximately 700 bp and a PrP-/- neomycin cassette
gene product of approximately 1700bp. Detection of the half-
genomic PrP transgene, expressing the N170S PrP construct, was
accomplished using primers pE2+ and Mut217 as described
previously [43]. PCR products were visualized via electrophoresis
in a 2% agarose gel.
Laboratory animals
All mice were housed at the Rocky Mountain Laboratories
(RML) in an AAALAC-accredited facility and experimentation
followed NIH RML Animal Care and Use Committee approved
protocols (NIH/RML Protocol #2007-31). This study was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. Mice were bred and genotyped at RML. For
use as controls, weanling C57BL/10Hsd mice were obtained from
Harlan Sprague Dawley, Madison, WI. Transgenic tga20 mice
were obtained from EMMA (Munich, Germany) [41].
Scrapie inoculations and animal observations
Micewere injectedintracerebrally(i.c.)with50mlofa1%(wt/vol)
dilution of brain homogenate pools from C57BL mice terminally ill
from 22L, RML, 79A or ME7 scrapie. Two stocks of RML scrapie
(RML-06, RML-81) were used. Titers of scrapie stocks were
determined in previous i.c. endpoint titration experiments and were
as follows; 22L=2.5610
9, ME7=4.0610
8, RML-06= 3.2610
8,
RML-81= 4.8610
8, 79A=1.6610
8 (units= 50% infectious dose
(ID50)/gm of brain). Brain homogenates were diluted for inocula-
tion in phosphate buffered balanced saline (PBBS) pH 7.2,
supplemented with 2% fetal bovine serum (Hyclone, Logan, UT).
Observations were made daily to assess clinical signs of scrapie
disease, which included ataxia, altered gait, wasting, kyphosis, hind
limb weakness, aimless wandering, somnolence, immobility and
leg clasping reflex. Mice with clinical signs were euthanized and
brain tissue was analyzed for PrPres by immunoblotting. Mice
with both clinical signs and PrPres by immunoblot were defined as
diseased, and the day of euthanasia was recorded as the incubation
period in the data presented. Uninoculated control transgenic
mice were followed up to 700 days of age and showed no clinical
signs of scrapie differing from normal signs of senescence. Several
uninoculated mice were analyzed by histopathology after eutha-
nasia at 465 days of age, and brain tissue had no detectable grey
matter vacuolation or abnormal PrPres deposition.
Statistical analysis of data in the coexpression experiment was
done by a one way ANOVA with Dunnett’s multiple comparison
test using GraphPad Prism software.
Immunoblot analysis
Tissue samples from mice were analyzed for PrPres and PrPsen
by immunoblot. Brain homogenates (20%w/v) were prepared in 10
mM Tris-HCl [pH 7.4] using a mini-beadbeater (Biospec products,
Bartlesville, OK). All homogenates were sonicated for 1 min using a
Vibracell cup-horn sonicator (Sonics, Newtown, NJ) as previously
described [40]. To test for PrPres, samples were proteinase K
treated as follows; 20 ml of a 20% (w/v) tissue homogenate was
adjusted to 100 mM Tris HCl (pH 8.3), 1% Triton X-100,1%
sodium deoxycholate and 50 mg/ml proteinase K (PK), in a total
volume of 31 ml. Tubes weremixed and incubated for 45 minutes at
37uC. The reaction was stopped by adding 2 mlo f1 0 0 m M
Pefabloc (Roche Diagnostics, Indianapolis, Indiana) and placed on
ice for 5 min. Samples tested for PrPsen were treated with
proteinase inhibitors: 10 mM leupeptin, 1 mM pepstatin A, and
7 mg/ml aprotinin. PrPsen samples were not treated with PK. An
equal volume of 2X Laemmli sample buffer (Biorad, Hercules, CA)
was added to both PrPsen and PrPres samples, and then tubes were
boiled 5 minutes. Samples were frozen at 220uC until the day of
analysis, when samples were thawed, reboiled for 5 minutes and
then electrophoresed on a 16% Tris-Glycine SDS-PAGE gel
(Invitrogen, Carlsbad,CA) and blotted to PVDF membranes
(Biorad) using a 7 minute transfer, program 3 (P3) on an iBlot
(Invitrogen) device. Immunoblots were blocked in a solution of
2.5% milk (Biorad) in 0.1 M Tris, 1.5M NaCl and 0.05% Tween20,
for 1 hour. Then blots were probed with D13 anti-PrP monoclonal
antibody [44],(InPro,SanFrancisco,CA)ata finalconcentrationof
0.2 mg/ml, followed by a peroxidase-conjugated anti-human IgG
secondary antibody (Sigma, St. Louis, MO) at a final dilution of
1:5000 in the blocking buffer described above. Bands were detected
using enhanced chemiluminescence substrate (ECL) as directed by
manufacturer (GE Healthcare, Pittsburgh, PA).
Histology and immunohistochemistry
For histopathological analysis mice were deeply anesthetized and
euthanizedbycervicaldislocation.Tissueswereremovedand placed
in 3.7% phosphate-buffered formalin for 3 to 5 days before
dehydration and embedding in paraffin. Serial 5 mm sections were
cut using a standard Leica microtome, placed on positively charged
glass slides and dried overnight at 43uC. Slides were then de-
paraffinized using standard procedures. Slides were stained with
hematoxylin and eosin and analyzed for pathological changes.
Immunohistochemical detection of PrPres using DAB chromogen
(DABMap kit;Ventana MedicalSystems,Tucson, AZ.)was doneas
follows: antigen retrieval and staining were performed using the
Ventana automated Discovery XT stainer. PrP antigens were
exposed by incubation in CC1 buffer (Ventana) containing Tris-
Borate-EDTA, pH 8.0 for 20 minutes at 95uC. Staining for PrP was
done using human anti-mouse PrP monoclonal antibody D13 at a
dilutionof1:500at37uCfor2 hours,followedbyabiotinylated anti-
human IgG at 1:500 (Jackson ImmunoResearch, West Grove, PA.),
and avidin-horseradish peroxidase with DAB as chromogen. Slides
were examined and photomicrographs were taken observed using
an Olympus BX51 microscope and Microsuite FIVE software.
Protein misfolding cyclic amplification (PMCA) assay
For preparation of normal brain homogenates containing PrPsen
to be used as the substrate for PMCA reactions healthy transgenic
mice expressing either PrP-170S (Tg330) or PrP-170N (Tga20) [41]
were deeply anesthetized and then perfused with PBS containing
5 mM EDTA. Brains were removed and homogenized in a
beadbeater at a concentration of 20% (w/v) in PMCA conversion
buffer (PBS containing 4 mM EDTA, 1% Triton X-100 and
complete mini-protease inhibitor cocktail (Roche), sterilized by
filtration with a 0.2 mm filter) then cooled on ice for 10–15 min.
Homogenates were diluted with PMCA conversion buffer to 10%
(w/v)thenclarified bya brief1500 X g spin[45].Supernatantswere
stored at 280u C in 1 ml aliquots until used in PMCA reactions.
Brain homogenates used as seeds for the PMCA reactions came
from clinically sick 22L or RML-infected C57BL/6 mice. Brains
were homogenized at a 20% (w/v) concentration using 0.1 M Tris
pH 7.4, then diluted in the same buffer to a final concentration of
10% (w/v) prior to storage at 280uC. Scrapie-positive brain
homogenates were used to ‘‘seed’’ normal brain homogenate in
the following manner. A 10% scrapie-positive brain homogenate
(seed) was added to normal brain homogenate (substrate) at
Strain-Specific Scrapie Resistance
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multiple 0.2ml reaction tubes (GeneMate, ISCBioexpress, Kays-
ville, Utah). One of these tubes was frozen as an unsonicated
control and the remaining tubes were repeatedly sonicated and
incubated as described below. Tubes were positioned in a plastic
tube rack PMCA adapter (Misonix, Farmingdale, NY) and placed
on the rim of a microplate horn of a Misonix Model 3000
microsonicator so that the 50 ml samples were immersed in the
sonicator bath. The microplate horn was covered with a plastic lid
to minimize evaporation from the water bath. The sonicator was
located inside an incubator set to 37uC and was programmed to
perform cycles, each consisting of a 40 second pulse of sonication
set at 60% maximum followed by a 30 min incubation. Forty-eight
cycles (i.e. 24 h) constituted one round of PMCA.
PMCA reaction tubes were removed from the sonicator and
vortexed and 10 ml of the 50 ml volume was sampled and mixed
with 10 ml PK at 100 mg/ml for a final PK concentration of
50 mg/ml. Samples were maintained at 37uC in a water bath for
one hour. The PK digestions were halted with 2 ml of 100 mM
Pefabloc (Roche Diagnostics) and placed on ice for 5 min. An
equal volume of 2X Laemmli sample buffer (Biorad, Hercules,
CA) was added to the PMCA samples, and then tubes were boiled
5 minutes. Samples were frozen at 220uC until the day of analysis,
when samples were thawed, and reboiled for 5 minutes. PMCA
products were visualized by SDS page gel electrophoresis and
immunoblotting as described above for brain tissues, with the
following exceptions. Gels were blotted to HyBond ECL
nitrocellulose membranes (GE Healthcare Life Sciences) instead
of PVDF membrane. Immunoblots were blocked in Near-Infrared
Fluorescence Western Blotting Blocking Buffer (Rockland Immu-
nochemicals Inc., Gilbertsville, PA) and PBS mixed in equal parts.
Primary antibody was D13 1:100 diluted supernatant derived from
CHO cells expressing the D13 antibody construct [44]. These cells
were obtained from R. Anthony Williamson, The Scripps
Research Institute, La Jolla, CA. The secondary antibody was
IRDye800CW-conjugated goat-anti-mouse IgG (LiCor, Lincoln,
NE) diluted at 1:10,000. Both antibodies were diluted in the
blocking buffer described above with the addition of 0.2% Tween
20. Finally, bands were detected using an Odyssey near-infrared
fluorescence scanner (LiCor). Groups were compared using a
Mann-Whitney test with GraphPad Prism software.
Results
Generation, breeding and PrP expression of transgenic
mice expressing mouse PrP-170S
To study the effect of the human PrP polymorphism, N171S, on
susceptibility to prion disease we generated transgenic mice
expressing mouse PrP-170S, the mouse homolog of the human
PrP-171S (Table 1). Five founder lines were produced on the
C57BL/6 background, and these were crossed serially to C57BL/
10 mice homozygous for the Edinburgh version of the PrP null
gene (Prnp-/-) [42]. Three lines of the transgenic mice (Tg290,
Tg330, and Tg340) with the Prnp-/- gene, and hemizygous for the
PrP-170S transgene, were obtained and used for further study.
Because PrPsen expression is known to influence scrapie
incubation period [41,46], we determined PrPsen levels in brain
by immunoblot. Both Tg330 and Tg340 mice expressed PrPsen at
levels 2 to 3-fold higher than were seen in non-transgenic control
C57BL/10 mice (Prnp+/+) which express PrP-170N (Figure 1).
Tg290 expressed approximately 10-fold lower PrP levels than did
control mice (data not shown). All three strains of PrP-170S mice
were next tested for susceptibility to scrapie infection.
Resistance to scrapie strains RML and 79A in PrP-170S
transgenic mice
Four strains of scrapie were used to test the influence of the
N170S polymorphism on susceptibility to TSE disease. In Tg330
and Tg340 mice, the 22L and ME7 scrapie strains produced
100% incidence of typical fatal prion disease with clinical signs
similar to control C57BL/10 mice (Table 2). Shorter incubation
periods were observed in the Tg330 and Tg340 mice than in
C57BL/10 mice, probably due to higher PrPsen expression levels
in the transgenic mice. The diagnosis of scrapie was confirmed by
the detection of PrPres in brain by immunoblotting. Brain PrPres
levels in transgenic mice were slightly less than those in control
mice, possibly due to shorter incubation periods (Figure 2A). In
Tg290 mice inoculation with scrapie strain 22L produced disease
in 6 of 8 mice at an average incubation period of 615 dpi (data not
shown). This lower incidence of disease and slower tempo
appeared to be related to the low PrPsen expression in Tg290
mice, and this line was not studied further.
Unexpected results were observed upon inoculation of RML
and 79A scrapie strains. Whereas control C57BL/10 mice were
uniformly susceptible to these two strains, transgenic Tg 330 and
Tg340 mice were quite resistant. Only two mice inoculated with
RML and two mice inoculated with 79A had clinical disease and
PrPres detectable by immunoblot (Figure 2), and all four occurred
at late times ranging from 439-545dpi (Table 2).
Brains were also examined microscopically for pathology and
presence of PrPres. In Tg mice infected with strains ME7 or 22L,
at the time of clinical disease vacuolation and PrPres deposition
were widespread in many brain regions (Figure 3A,B,C) similar to
non-transgenic control mice (not shown). In contrast, after
infection with strains 79A or RML, Tg mice with clinical signs
or PrPres detectable by immunoblot showed localized vacuolation
Figure 1. Immunoblot detection of PrPsen from C57BL/10 and transgenic mice. Blot was developed using anti-PrP monoclonal antibody
D13 and enhanced chemiluminescence exposure for 1 minute. Lanes 1-3 show brain PrP-170N expression level in a C57BL/10 mouse, lanes 4-6 and
lanes 7-9 show brain PrP-170S expression in Tg330 and Tg340 mice. For each mouse, three lanes beginning on the left were loaded with 0.5, 0.25 and
0.125 mg tissue equivalents, respectively. Comparison of these groups of samples suggested 2-3-fold greater PrP expression in the transgenic mice
versus C57BL/10 mice. Several different individual transgenic mouse brains were also studied, and results confirmed the data presented here. Tg330
and Tg340 also expressed detectable levels of PrPsen in kidney, cecum, adrenal gland, heart, spleen and skeletal muscle (immunoblots not shown).
doi:10.1371/journal.ppat.1002275.g001
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thalamus, hippocampus and pons. In addition, ten RML or 79A-
infected Tg mice, who were negative for PrPres by immunoblot,
had subclinical infection as shown by brain PrPres deposits mainly
localized to the vestibular nuclei in the pons or to the anterodorsal
region of the thalamus detected at 545-603dpi (Figure 3I,J,K,L). In
these same areas gray matter vacuolation was either absent or
minimal (Figure 3F). Detection of these subclinical mice provided
evidence of a higher incidence of infection than was shown by
standard clinical observation and analysis of brain PrPres by
immunoblotting. Perhaps these mice should be considered
preclinical as they might have developed clinical disease if allowed
to survive for a longer time. These results suggested that infection
of Tg PrP-170S mice by RML or 79A scrapie occurred at slow
and reduced levels, and this appeared to account for the rare
presence of clinical signs in this experiment.
In vitro generation of RML and 22L PrPres using protein
misfolding cyclic amplification (PMCA)
Our in vivo experiments showed a dramatic difference in the
tempo and levels of PrPres generation in brains of Tg330 and
Tg340 mice after infection with scrapie strains RML and 79A
compared to strains 22L and ME7. Possibly a delay in PrP
conversion and subsequent accumulation of PrPres might account
for our results. Therefore to test PrP conversion under in vitro
conditions we used the PMCA cell-free system [47]. As a source of
PrPsen, brain homogenates derived from either Tga20 mice
expressing PrP-170N or Tg330 mice expressing PrP-170S were
used, and these reactions were initiated by seeding with PrPres
from PrP-170N mice infected with scrapie strains 22L or RML.
Surprisingly, RML PrPres seed generated PrPres conversion
with both PrP-170N and PrP-170S brain homogenates. Quanti-
fication of PrPres produced in the PMCA revealed slightly greater
amounts of product in the PrP-170N reactions, but these
differences were not statistically significant (Figure 4A, 4B and
4C). However, the positive conversion of PrP-170S by RML
PrPres indicated that there was not a basic inability of RML
scrapie PrPres to convert PrP-170S. This was in contrast to the
slow conversion in vivo requiring over 400 days when Tg330 and
Tg340 mice were inoculated with RML scrapie (Figures 2 and 3).
In similar PMCA reactions 22L PrPres seed also gave higher
PrPresgenerationusingPrP-170NcomparedtoPrP-170Ssubstrate.
Thesedifferences werestatisticallydifferent(Figure4D,4E,4F),and
might in part be due to the higher PrP expression in substrates from
tga20 versus Tg330 mice. In summary, comparison of PrP-170N
Figure 2. Immunoblot analysis of PrPres in scrapie-infected
mice. (A) Panel A shows immunoblots of brain homogenates tested
using both 0.5mg and 0.25mg brain equivalents per lane. PrPres levels
in clinical Tg330 mice (#255 and #019) were slightly lower than levels
seen in clinical C57BL/10 mice. All C57BL/10 and Tg330 mice inoculated
with 22L and ME7 scrapie were positive for PrPres by western blot at
the time of clinical disease. In panels B and C, lanes 1 and 2 had 0.5 mg
brain equivalents and other lanes had 1.0mg. (B) RML (stock 06)
inoculations. Of fifteen transgenic mice tested, two (#573 and 778)
were positive for PrPres at 451 and 518 days respectively. Four of the 13
PrPres-negative mice are also shown. RML (stock 81) inoculation of 14
mice resulted in none positive for PrPres by immunoblot (not shown).
(C) 79A inoculations. Of fourteen transgenic mice tested, two mice
(#657 and 470) were positive for PrPres at 439 and 545 dpi respectively.
Four of the 12 PrPres-negative mice are also shown.
doi:10.1371/journal.ppat.1002275.g002
Table 2. Susceptibility of transgenic and C57BL/10 mice to four strains of scrapie.
Mouse strains
C57BL/10 Tg330 Tg340
Scrapie strains
a Diseased/total Incubation period
b Diseased/total Incubation period
b Diseased/total Incubation period
b
22L 11/11 14165 18/18 10969 5/5 12867
ME7 8/8 15366 8/8 9963 11/11 10164
RML-06 10/10 17968 0/8 na
c 2/7 451, 518
RML-81 8/8 14666 0/7 na 0/7 na
79A 8/8 13266 2/7 439, 545 0/7 na
a= For strain RML, two different stocks, RML-06 and RML-81 were studied.
b= Incubation period is average days post-inoculation to disease +/2 standard deviation.
c = not applicable (mice did not develop disease during 545-603 days of observation).
doi:10.1371/journal.ppat.1002275.t002
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PLoS Pathogens | www.plospathogens.org 5 September 2011 | Volume 7 | Issue 9 | e1002275Figure 3. Histopathological analysis of brain tissue from transgenic mice inoculated with various scrapie strains. (A) (B) ME7-
inoculated transgenic mouse with clinical signs at 98 dpi showing cerebral cortex with extensive PrPres deposition by D13 staining (A) and
vacuolation by H&E staining (B). (C) 22L-inoculated transgenic mouse with clinical signs at 123dpi showing PrPres deposition in hypothalamus. (D)
H&E stained area of pons from control uninoculated 465 day old mouse. (E) Vacuolation of pons in 79A-inoculated transgenic mouse with clinical
disease at 545dpi. (F) Several pleomorphic and multiloculated vacuoles (arrows) seen by H&E staining in anterodorsal area of thalamus of RML-
inoculated mouse at 603dpi. Vacuoles were not seen in other brain regions of this mouse. Mouse was negative for clinical signs and for PrPres by
immunoblot. (G) D13 anti-PrP staining of pons from a 465 day old uninoculated control mouse. Note light brown PrPsen staining in background. (H)
D13-stained pons from a 79A-inoculated mouse positive for clinical signs and PrPres by immunoblot at 545 dpi. Localized areas with similar stained
aggregates were also seen in the thalamus, hypothalamus and hippocampus of this mouse. (I) D13-positive PrPres in anterodorsal area of thalamus of
an RML-inoculated mouse negative for both PrPres by immunoblot and clinical signs at 603 dpi. Deposits were not detected in other brain regions.
Light staining in lower part of panel is PrPsen which was also seen in uninoculated mice. (J) Positive D13 staining around cells and along linear
structure of extracellular space or possibly axons (arrows) in pons from an RML-inoculated mouse negative for both PrPres by immunoblot and
clinical signs at 545dpi. No other brain regions had detectable staining. (K) Stained PrPres aggregates in anterodorsal thalamus from 79A-inoculated
mouse negative for clinical signs and for PrPres by immunoblot at 545dpi. Similar aggregates were also seen in the pons. (L) Stained PrPres
aggregates in pons from a 79A-inoculated mouse negative for clinical signs and for PrPres by immunoblot at 545 dpi. PrPres was detected only in a
small area of the pons. Diffuse staining in background is PrPsen. Scale bar is 100 mm and applies to all panels.
doi:10.1371/journal.ppat.1002275.g003
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no evidence that in vitro conversion of PrP-170S by RML PrPres
was abnormal as detected by PMCA.
Infectivity studies in mice expressing both PrP-170S and
PrP-170N
In numerous previous studies expression of two different PrP
alleles from the same or different species has been shown to reduce
the level of prion infection as well as the incidence and tempo of
disease [22,48,49]. The resistance of the Tg330 and Tg340 mice
to RML and 79A scrapie prompted us to test whether the presence
of both PrP-170S and PrP-170N in the same mouse would result
in lower disease incidence or increased incubation times.
To investigate this question, 22L or RML scrapie was inoculated
into mice expressing two PrP alleles, one allele of the PrP-170S
transgene and one allele of the mouse Prnp gene expressing
Figure 4. PMCA reactions comparing PrP-170N and PrP-170S as PrPsen substrates. Panels A, B, D, and E show immunoblots of PMCA
products visualized on the LiCOR Odyssey Scanner. RML (A and B) or 22L (D and E) scrapie-infected brain homogenates diluted 1:400 were used to
seed two different brain homogenate substrates: 170N from Tga20 mice (A and D) and 170S from Tg330 mice (B and E). For all gels, lane 1 contains
unseeded Tga20 brain homogenate (5 mg brain equivalent of Tga20 brain homogenate), which was used as a control to show differences in
detection sensitivity (gain setting) on the Odyssey scanner. For example, gain was increased for panels A and B compared to D and E because of the
lower signal obtained with the RML seed in both 170N and 170S substrates. Other lanes contain 3.5 ml of PK-digested sonicated reaction product
(lanes 3–8) or unsonicated freeze–control (lane 2). Amplification is evident by comparison of the unsonicated lanes with corresponding sonicated
lanes. Results shown are representative of several independent experiments. Panels C and F show quantitation of PrPres as integrated intensity, i.e.
the quantitative measure of protein detected by the scanner, from each lane of experiments shown in A, B, D, and E (using LyCor Odyssey scanner
and software). Closed circles represent values for sonicated samples minus values for unsonicated freeze-control samples. Groups were compared by
a 2-tailed nonparametric Mann Whitney test. For the 22L seed, the 170N and 170S substrates were significantly different (P,0.01), and for the RML
seed, the 170N and 170S were not significantly different (P=0.093).
doi:10.1371/journal.ppat.1002275.g004
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were inoculated as controls. With the 22L strain, mice expressing
both 170S and 170N PrP had significantly faster incubation times
(106–115dpi) than mice expressing only 170N (259 dpi) (Table 3).
Therefore interference between these PrP variants did not seem to
occur.Thedecrease inincubationperiodseen whenboth PrPalleles
were expressed could be explained if the PrP-170S variant could
contribute to a more rapid incubation time, as would be predicted
by the susceptibility of the original Tg330 and Tg340 mice to 22L
infection.
In the case of strain RML, the expression of both alleles was
associated with a decrease in incubation time compared to
expression of PrP-170N alone, but these differences were not
statistically significant (Table 3). Therefore, the more highly
expressed PrP-170S protein appeared to contribute very little
towards accelerating the disease tempo in these mice, and also
there was no evidence for interference. This outcome might be
predicted from the very low susceptibility of the PrP-170S
transgenic mice to RML scrapie infection (Table 2). In summary,
the PrP-170S variant appeared to be ‘‘neutral’’ during the
infection by RML scrapie, showing no interference with the
PrP-170N in the co-expression experiment.
Discussion
In the present experiments the influence of a normal human
prion protein gene allelic variation, N171S, on prion disease
susceptibility was studied in a mouse system using transgenic mice
expressing the mouse homolog, N170S. Susceptibility to prion
disease induced by mouse scrapie strains, 22L and ME7, was
identical in control mice expressing PrP-170N versus transgenic
mice expressing PrP-170S. In contrast, after inoculation with
scrapie strains, RML or 79A, mice expressing PrP-170S were
markedly resistant compared to control mice expressing PrP-
170N. Of the 43 transgenic mice inoculated with these two scrapie
strains, disease occurred only after 439 days and this was seen in
only 4 mice. An additional 10 mice had subclinical infection after
545–603 days, as shown by detection of PrPres by IHC, however
the remaining 29 mice had no evidence of clinical signs or PrPres
accumulation in brain after observation up to 603 days. These
results demonstrated that mice expressing PrP-170S were highly
resistant to infection by strains RML and 79A, but this resistance
was strain-specific since there was no resistance to two other strains
(ME7 and 22L).
One explanation for the scrapie strain-specific differences seen
in our experiments may lie in the origins of the scrapie strains used
(Figure 5). Strain ME7 was the result of a passage of natural
scrapie in Suffolk sheep directly to mice and therefore was not
related to other scrapie strains[50]. On the other hand, 22L, RML
and 79A share a common origin in that they were all derived from
the Moredun Institute’s sheep scrapie brain pool 1(SSBP/1)[51].
However, there were major differences in the passage history of
each of these 3 strains, and strains 79A and RML were more
closely related to each other than to strain 22L [51,52] (Figure 5).
This may explain the similar resistance pattern of strains 79A and
RML in PrP-170S mice.
Although the biochemical explanation for scrapie strains in
general remains a mystery at this time, it has been hypothesized
that PrPres from each strain adopts a slightly different conforma-
tion which is conferred on successive PrPsen molecules as they are
converted to PrPres [53]. Accordingly, our current data might be
explained by the conformational selection model of prion strains
and species barriers [54,55] which was first developed to explain
prion strain differences involving the Sup35 protein in yeast
[56,57,58]. This model suggests that only a subset of all possible
PrPres conformations is compatible with any individual PrP
primary structure. Thus incompatibility between the infecting
prion strain and the host PrP would result in a transmission barrier
[54]. For example, mouse PrP-170S might easily assume the
conformations required by strains ME7 or 22L, but might be less
adept at assuming the conformations associated with strains RML
or 79A. In practice most mutations studied lead to altered
incubation periods [30,31], but when strong species barriers exist,
either no transmission or low level subclinical cross-species
transmission has been observed [59,60,61].
Another possible explanation for our results is that in vivo
conversion of PrP-170S by RML or 79A strains might generate
PrPres with a lower than usual stability. This might be due to
either high dissociation of PrPres into smaller oligomers or
increased susceptibility of PrPres to catabolic degradation.
However, we were not able to detect any evidence for the
presence of PrPres with increased susceptibility to proteinase K in
PrP-170S transgenic mice infected by either RML or 79A scrapie
strains (data not shown).
Effects of PrP amino acid variations on prion disease species and
strain transmission barriers in some cases appear to correlate with
differences in PrP conversion. For example, sheep homozygous for
PrP with V136R154Q 171 or A136R154Q 171 show opposite patterns
of susceptibility to scrapie strains SSBP1 and CH1641 [62,63],
and in vitro generation of PrPres in PMCA reactions agreed with
the in vivo resistance observed [64]. However, when we tested PrP
conversion in vitro using PMCA, both 22L and RML PrPres were
Table 3. Effect of coexpression of 170N and 170S PrPsen on prion disease after inoculation with scrapie strains 22L or RML.
22L RML
Mouse Strain PrPsen
a Genotype Diseased/total Incubation period
b Diseased/total Incubation period
Prnp+/- 0.5X 170N/-
c 11/11 25965 8/8 299670
Tg330+/2Prnp+/2 2.5-3.5X 170N/S 5/5 106614
d 5/5 231637
e
Tg340+/2Prnp+/2 2.5-3.5X 170N/S 5/5 115615
d 3/4 244656
e
a = expression of PrPsen relative to C57BL/10 Prnp+/+ mouse.
b = incubation period is average days post inoculation +/2 standard deviation to disease after inoculation with 22L or RML (stock RML-81) scrapie as described in the
methods.
c = Prnp+/2 mice have only one PrP allele and this allele expresses 170N.
d=p ,0.001 compared to Prnp+/2 mice using a 1-way ANOVA with Dunnett’s multiple comparison test.
e = After RML infection, neither Tg330 nor Tg340 were significantly different from Prnp+/2 mice when compared using a 1-way ANOVA with Dunnett’s multiple
comparison test (P=0.1457).
doi:10.1371/journal.ppat.1002275.t003
Strain-Specific Scrapie Resistance
PLoS Pathogens | www.plospathogens.org 8 September 2011 | Volume 7 | Issue 9 | e1002275able to seed the generation of PrPres derived from PrP-170S
(Figure 4). This conversion of PrP-170S by RML scrapie was in
contrast to the ineffective production of disease and slow and low
PrPres generation in PrP-170S mice infected with RML scrapie.
Biological and biochemical differences between conditions in brain
tissue of live mice and PMCA test tube reactions might account for
the discrepancies between our in vivo and in vitro results. Similar
discrepancies between PrPres generation by PMCA in vitro and
clinical susceptibility have been noted previously, and in some
cases strong in vivo transmission barriers between species have
been easily overcome by using PMCA with minor alterations in
conditions [65]. Thus PrP conversion by PMCA would appear to
be less selective than in vivo infection by TSE agents.
Interestingly, the N171S polymorphism in humans (homologous
to the N170S change in our Tg330 and Tg340 mice) occurs near
other PrP residues implicated in influencing PrP structure and
folding as well as susceptibility to prion diseases in animals. For
example, alterations in PrP folding in vitro have been noted after
mutations homologous to human residues 168 [66] and 170 [67].
At the structural level, PrP mutation at human residue 170
(S170N) appears to create a stabilized loop structure located near
residues 165-175 [68], and this change may influence susceptibility
to CWD and other prion agents [37,38]. However, others have
reported no effect of S170N on species-specific PrP conversion in
vitro in a mouse-hamster system [69,70,71]. In contrast, resistance
of rabbits to prion disease appears to be associated with a serine at
human PrP residue 174 [72]. Similarly, the sheep polymorphism
at residue 171 (human residue 168) is important in the resistance
of sheep to classical scrapie strains [6,73,74]. Possibly the N171S
polymorphism examined in the present study might be able to
modulate prion disease because of its location near the PrP loop
structure and other nearby influential residues.
In humans, familial prion diseases have been associated with
PrP mutations in the near vicinity of the PrP loop structure, i.e.
Q160X [75], Y163X [76], D178N [77] and V180I [78]. The
N171S polymorphism is not by itself associated with familial prion
disease [26]. However, a previous study identified a family with an
unusual psychiatric disorder associated with PrP N171S [79].
More recently, in an African-American family with unusual
psychiatric signs and sleep abnormalities preceding onset of
familial CJD, disease was linked to expression of a PrP molecule
containing both PrP N171S and D178N mutations [80].
Interestingly this is the first family with African ancestry where
the D178N mutation has been detected, as the 12 previously
reported families were of European or Japanese descent [78,80].
This family might be an example where the N171S polymorphism
altered the clinical disease signs when expressed in combination
with a known pathogenic PrP mutation. It remains unclear
whether this effect is mediated by a direct influence of these
mutations on PrP misfolding or whether indirect effects involving
other non-PrP molecules might also play a role. Nevertheless, the
fact that the N171S polymorphism is present in healthy
populations of humans [81], suggests that N171S is likely non-
pathogenic by itself and that there may even be a selective
advantage for maintaining its presence in human genomes.
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Figure 5. History of scrapie strains used. The derivations and passage history of strains ME7 [50], 79A [51], Chandler (RML) [52] and 22L [51] are
shown. Chandler (RML) and 79A are both derived from the ‘‘drowsy goat’’ line [82], and therefore are likely to be more closely related to each other
than to strains ME7 or 22L.
doi:10.1371/journal.ppat.1002275.g005
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